The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.
The current biotech environment can apparently support an industry-record IPO and simultaneously hamper efforts to raise half a billion dollars.
Summit Therapeutics ditched plans for …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to…
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in…
The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted…
Parabilis Medicines prices a $670M IPO — the biggest biotech Nasdaq debut ever — to fund its experimental desmoid-tumor drug…
Parabilis Medicines, the decade-old and well-funded
Summit pulls $500M share sale a day after announcing it
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Parabilis sets a record with a $670M biotech IPO
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Novo underwhelmed by drug it once fought Pfizer for
Apotex Health upsizes initial public offering to sell $1.3 billion in shares
